A Camzyos pill bottle
BMS updated its 340B contract pharmacy pricing policy to address how it will handle 340B discounts on its new heart medicine Camzyos.

BMS Updates its Conditions on 340B Pricing Involving Contract Pharmacy

Drug manufacturer Bristol Myers Squibb (BMS) yesterday updated its 340B contract pharmacy pricing policy to address how it will handle 340B discounts on its new heart medicine Camzyos, a potential blockbuster product.

Camzyos is a first-in-class treatment for symptomatic obstructive hypertrophic cardiomyopathy. To minimize the risk of patient heart failure and/or fetal harm, its distribution is limited under a Risk Evaluation and Mitigation Strategy (REMS). It can be dispensed only by certified pharmacies only to authorized patients.

Drug manufacturer Bristol Myers Squibb (BMS) yesterday updated its 340B contract pharmacy pricing policy to address how it will handle 340B discounts on its new heart medicine Camzyos, a potential blockbuster product.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

×

*Sign up for news summaries and alerts from 340B Report

Site Footer